167 related articles for article (PubMed ID: 35740636)
21. Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study.
Hammers HJ; Plimack ER; Infante JR; Rini BI; McDermott DF; Lewis LD; Voss MH; Sharma P; Pal SK; Razak ARA; Kollmannsberger C; Heng DYC; Spratlin J; McHenry MB; Amin A
J Clin Oncol; 2017 Dec; 35(34):3851-3858. PubMed ID: 28678668
[TBL] [Abstract][Full Text] [Related]
22. Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies for metastatic renal-cell carcinoma: a multicenter retrospective study.
Kido K; Hatakeyama S; Numakura K; Tanaka T; Oikawa M; Noro D; Hosogoe S; Narita S; Inoue T; Yoneyama T; Ito H; Nishimura S; Hashimoto Y; Kawaguchi T; Habuchi T; Ohyama C
Int J Clin Oncol; 2021 Jan; 26(1):154-162. PubMed ID: 33067647
[TBL] [Abstract][Full Text] [Related]
23. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma.
Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Fernández-Pello S; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
Eur Urol; 2021 Mar; 79(3):339-342. PubMed ID: 33357997
[TBL] [Abstract][Full Text] [Related]
24. Salvage nivolumab and ipilimumab after prior anti-PD-1/PD-L1 therapy in metastatic renal cell carcinoma: A meta-analysis.
Yang Y; Mori SV; Li M; Hinkley M; Parikh AB; Collier KA; Miah A; Yin M
Cancer Med; 2022 Apr; 11(7):1669-1677. PubMed ID: 35138046
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of immune checkpoint inhibitors in elderly patients with metastatic renal cell carcinoma.
Nemoto Y; Ishihara H; Nakamura K; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Tanabe K; Kondo T; Takagi T
Int Urol Nephrol; 2022 Jan; 54(1):47-54. PubMed ID: 34704214
[TBL] [Abstract][Full Text] [Related]
26. External validation of the systemic immune-inflammation index as a prognostic factor in metastatic renal cell carcinoma and its implementation within the international metastatic renal cell carcinoma database consortium model.
Chrom P; Zolnierek J; Bodnar L; Stec R; Szczylik C
Int J Clin Oncol; 2019 May; 24(5):526-532. PubMed ID: 30604160
[TBL] [Abstract][Full Text] [Related]
27. Predictive Impact of Early Changes in Serum C-Reactive Protein Levels in Nivolumab Plus Ipilimumab Therapy for Metastatic Renal Cell Carcinoma.
Tachibana H; Nemoto Y; Ishihara H; Fukuda H; Yoshida K; Iizuka J; Hashimoto Y; Kondo T; Tanabe K; Takagi T
Clin Genitourin Cancer; 2022 Feb; 20(1):e81-e88. PubMed ID: 34772629
[TBL] [Abstract][Full Text] [Related]
28. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial.
Cella D; Grünwald V; Escudier B; Hammers HJ; George S; Nathan P; Grimm MO; Rini BI; Doan J; Ivanescu C; Paty J; Mekan S; Motzer RJ
Lancet Oncol; 2019 Feb; 20(2):297-310. PubMed ID: 30658932
[TBL] [Abstract][Full Text] [Related]
29. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.
Auvray M; Auclin E; Barthelemy P; Bono P; Kellokumpu-Lehtinen P; Gross-Goupil M; De Velasco G; Powles T; Mouillet G; Vano YA; Gravis G; Mourey L; Priou F; Rolland F; Escudier B; Albiges L
Eur J Cancer; 2019 Feb; 108():33-40. PubMed ID: 30616146
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of systemic immune-inflammation index in non-metastatic clear cell renal cell carcinoma with tumor thrombus.
Gu Y; Fu Y; Pan X; Zhou Y; Ji C; Zhao T; Miao H; Lv H; Da J; Ge J; Wang L; Qu L; Ge S; Guo H; Zhou W
Front Oncol; 2023; 13():1117595. PubMed ID: 36776325
[TBL] [Abstract][Full Text] [Related]
31. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.
Doki Y; Ajani JA; Kato K; Xu J; Wyrwicz L; Motoyama S; Ogata T; Kawakami H; Hsu CH; Adenis A; El Hajbi F; Di Bartolomeo M; Braghiroli MI; Holtved E; Ostoich SA; Kim HR; Ueno M; Mansoor W; Yang WC; Liu T; Bridgewater J; Makino T; Xynos I; Liu X; Lei M; Kondo K; Patel A; Gricar J; Chau I; Kitagawa Y;
N Engl J Med; 2022 Feb; 386(5):449-462. PubMed ID: 35108470
[TBL] [Abstract][Full Text] [Related]
32. Prognostic Impact of Baseline Neutrophil-to-Eosinophil Ratio in Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab Therapy in Second or Later Lines.
Gil L; Alves FR; Silva D; Fernandes I; Fontes-Sousa M; Alves M; Papoila A; Da Luz R
Cureus; 2022 Feb; 14(2):e22224. PubMed ID: 35340486
[TBL] [Abstract][Full Text] [Related]
33. Primary Tumor Shrinkage and the Effect on Metastatic Disease and Outcomes in Patients With Advanced Kidney Cancer With Intermediate or Poor Prognosis Treated With Nivolumab Plus Ipilimumab or Cabozantinib.
Iacovelli R; Ciccarese C; Maruzzo M; Atzori F; Galli L; Scagliarini S; Massari F; Verzoni E; Cannella A; Maratta MG; Caserta C; Bimbatti D; Deppieri FM; Dessi M; Paolieri F; Riccardi F; Bracarda S; De Giorgi U; Basso U; Tortora G; Procopio G
Clin Genitourin Cancer; 2022 Oct; 20(5):498.e1-498.e9. PubMed ID: 35768316
[TBL] [Abstract][Full Text] [Related]
34. Comparative Efficacy of Combination Therapy of Ipilimumab Plus Nivolumab for Non-clear Cell Renal Cell Carcinoma.
Bando Y; Furukawa J; Okamura Y; Hara T; Terakawa T; Nakano Y; Fujisawa M
Anticancer Res; 2022 Feb; 42(2):973-979. PubMed ID: 35093897
[TBL] [Abstract][Full Text] [Related]
35. Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma.
Tachibana H; Kondo T; Ishihara H; Fukuda H; Yoshida K; Takagi T; Izuka J; Kobayashi H; Tanabe K
Jpn J Clin Oncol; 2021 Apr; 51(4):646-653. PubMed ID: 33212488
[TBL] [Abstract][Full Text] [Related]
36. The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitors.
Yücel KB; Yekedüz E; Karakaya S; Tural D; Ertürk İ; Erol C; Ercelep Ö; Öztaş NŞ; Arslan Ç; Uçar G; Küçükarda A; Sever ÖN; Kılıçkap S; Can O; Yazgan SC; Öksüzoğlu B; Karadurmuş N; Şendur MA; Ürün Y
Sci Rep; 2022 Oct; 12(1):16559. PubMed ID: 36192500
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214.
Escudier B; Motzer RJ; Tannir NM; Porta C; Tomita Y; Maurer MA; McHenry MB; Rini BI
Eur Urol; 2020 Apr; 77(4):449-453. PubMed ID: 31732098
[TBL] [Abstract][Full Text] [Related]
38. Serum C-reactive Protein Level Predicts Overall Survival for Clear Cell and Non-Clear Cell Renal Cell Carcinoma Treated with Ipilimumab plus Nivolumab.
Yano Y; Ohno T; Komura K; Fukuokaya W; Uchimoto T; Adachi T; Hirasawa Y; Hashimoto T; Yoshizawa A; Yamazaki S; Tokushige S; Nishimura K; Tsujino T; Nakamori K; Yamamoto S; Iwatani K; Urabe F; Mori K; Yanagisawa T; Tsuduki S; Takahara K; Inamoto T; Miki J; Kimura T; Ohno Y; Shiroki R; Azuma H
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428750
[TBL] [Abstract][Full Text] [Related]
39. Role of immune checkpoint inhibitor-based therapies for metastatic renal cell carcinoma in the first-line setting: A Bayesian network analysis.
Wang J; Li X; Wu X; Wang Z; Zhang C; Cao G; Zhang X; Peng F; Yan T
EBioMedicine; 2019 Sep; 47():78-88. PubMed ID: 31439476
[TBL] [Abstract][Full Text] [Related]
40. Impact of Cytoreductive Nephrectomy Following Nivolumab Plus Ipilimumab Therapy for Patients With Advanced Renal Cell Carcinoma.
Shirotake S; Miyama YU; Baba Y; Tajima H; Okada Y; Nakazawa K; Usami Y; Yasuda M; Igarashi D; Kaneko GO; Kanao K; Oyama M; Nishimoto K
Anticancer Res; 2022 May; 42(5):2727-2735. PubMed ID: 35489743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]